Eukaryotic expression of the broad-spectrum chemokine receptor antagonist vMIP-II and its effects on T-cell function in vitro and in vivo
| Autor: | Wolf-Henning Boehncke, Jeannette Pfeffer, Ralf Ludwig, Simone A. Rubant, Roland Kaufmann, Petra Schulze-Johann, Josef Pfeilschifter, Heinfried H. Radeke |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Male
Chemokine T-Lymphocytes/drug effects/*immunology Chemokine receptor CCR5 Anti-HIV Agents T cell T-Lymphocytes Anti-Inflammatory Agents Recombinant Proteins/chemistry Dermatology In Vitro Techniques Dermatitis Contact Biochemistry CCL5 Chemokine Receptor Antagonist Chemokine receptor Mice medicine Chemokines/*pharmacology CCL17 Animals Humans Anti-Inflammatory Agents/pharmacology Lymphocytes Molecular Biology Anti-HIV Agents/*pharmacology biology Chemotaxis Receptors Chemokine/*antagonists & inhibitors Lymphocytes/metabolism Molecular biology Recombinant Proteins Mice Inbred C57BL medicine.anatomical_structure Immunology biology.protein XCL2 Receptors Chemokine Chemokines |
| Zdroj: | Experimental Dermatology, Vol. 15, No 8 (2006) pp. 634-642 |
| ISSN: | 0906-6705 |
| Popis: | Pro-inflammatory chemokines and their receptors exhibit elementary functions in cell migration and in Th1-driven inflammatory conditions. One therapeutic strategy to prevent accumulation of pro-inflammatory immune cells is the use of specific chemokine receptor antagonists. An interesting and promising candidate in this context is the viral antagonist MIP-II (vMIP-II) that acts on a broad spectrum of chemokine receptors. To study the in vitro and in vivo effects of vMIP-II on pro-inflammatory chemokine receptor function, we further characterized an ovalbumin-specific murine central memory Th1IF12 clone by using RT-PCR, cDNA array and cytometry. Using in vitro chemotaxis assays we show that eukaryotically generated vMIP-II strongly inhibited migration of CCL2- or CCL5-stimulated Th1 IF12 cells. Using intravital microscopy, we observed that CCL5 induced rolling of Th1 cells in the ear vasculature of C57Bl/6 mice. Pre-treatment with vMIP-II significantly reduced CCL5-induced rolling of Th1 cells to basal levels, indicating, that vMIP-II is also active in vivo (proportion of rolling cells: 19.4 +/- 3.8%, 39.8 +/- 2.9% and 26.1 +/- 3.2%). In addition, investigating the anti-inflammatory action of vMIP-II in adoptive transfer of immunity and dinitrofluorobenzene-induced cutaneous hypersensitivity reaction using C57Bl/6 mice, we show a direct inhibitory effect of vMIP-II on the sensitization phase [Delta ear swelling 62 and 37 cm x 10(-3) for controls and vMIP-II treated mice (2.5 mg/kg), respectively] and effector phase (Delta ear swelling 14.8 and 3.6 cm x 10(-3) for controls and vMIP-II treated mice (2.5 mg/kg), respectively) of cutaneous hypersensitivity. These data indicate that vMIP-II is a promising agent to interfere with chronic inflammatory (skin) diseases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|